Arrowstreet Capital’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | – | Sell |
|
|||||
2025
Q1 | $746K | Sell |
|
|||||
2024
Q4 | $4.17M | Sell |
|
|||||
2024
Q3 | $8.02M | Buy |
|
|||||
2024
Q2 | $56.5M | Buy |
|
|||||
2024
Q1 | – | Sell |
|
|||||
2023
Q4 | $62.2M | Sell |
|
|||||
2023
Q3 | $117M | Buy |
|
|||||
2023
Q2 | $50.4M | Buy |
|
|||||
2023
Q1 | $15.5M | Buy |
|
|||||
2022
Q4 | $1.45M | Sell |
|
|||||
2022
Q3 | $2.72M | Sell |
|
|||||
2022
Q2 | $196M | Buy |
|
|||||
2022
Q1 | $143M | Buy |
|
|||||
2021
Q4 | $103M | Buy |
|
|||||
2021
Q3 | $37.2M | Buy |
|
|||||
2021
Q1 | – | Sell |
|
|||||
2020
Q4 | $46.5M | Sell |
|
|||||
2020
Q3 | $86.5M | Sell |
|
|||||
2020
Q2 | $200M | Sell |
|
|||||
2020
Q1 | $234M | Sell |
|
|||||
2019
Q4 | $231M | Sell |
|
|||||
2019
Q3 | $216M | Sell |
|
|||||
2019
Q2 | $221M | Sell |
|
|||||
2019
Q1 | $330M | Sell |
|
|||||
2018
Q4 | $303M | Buy |
|
|||||
2018
Q3 | $110M | Sell |
|
|||||
2018
Q2 | $135M | Buy |
|
|||||
2018
Q1 | $109M | Sell |
|
|||||
2017
Q4 | $137M | Buy |
|
|||||
2017
Q3 | $27.8M | Buy |
|
|||||
2017
Q2 | – | Sell |
|
|||||
2017
Q1 | $319K | Buy |
|
|||||
2016
Q4 | – | Sell |
|
|||||
2016
Q3 | $13.2M | Buy |
|
|||||
2016
Q2 | $7.43M | Sell |
|
|||||
2016
Q1 | $155M | Sell |
|
|||||
2015
Q4 | $458M | Buy |
|
|||||
2015
Q3 | $372M | Buy |
|
|||||
2015
Q2 | $315M | Buy |
|
|||||
2015
Q1 | $186M | Sell |
|
|||||
2014
Q4 | $252M | Buy |
|
|||||
2014
Q3 | $192M | Buy |
|
|||||
2014
Q2 | $73.8M | Buy |
|
|||||
2014
Q1 | – | Sell |
|
|||||
2013
Q4 | $24.2M | Sell |
|
|||||
2013
Q3 | $29.4M | Sell |
|
|||||
2013
Q2 | $38.8M | Buy |
|